Top

International Journal of Colorectal Disease

Published in:

01-09-2012 | Review

Systematic review of medical therapy to prevent recurrent diverticulitis

Authors: Çagdas Ünlü, Lidewine Daniels, Bart C. Vrouenraets, Marja A. Boermeester

Published in: International Journal of Colorectal Disease | Issue 9/2012

Abstract

Aim and background

One of today’s controversies remains the prevention of recurrent diverticulitis. Current guidelines advise a conservative approach, based on studies showing low recurrence rates and a high operative morbidity and mortality. Conservative measures in prevention recurrence are dietary advises and medical therapies, including probiotics and 5-aminosalicylic acid.

Objectives

The aim of this systematic review is to assess whether medical or dietary therapies can prevent recurrent diverticulitis after a primary episode of acute diverticulitis.

Method and search strategy

We searched different databases for papers published between January 1966 and January 2011.

Study selection

Clinical studies were eligible for inclusion if they assessed the prevention of recurrent diverticulitis with a medical or dietary therapy. Exclusion criteria were studies without a control group.

Results

Three randomized controlled trials (RCT), all with a Jadad quality score of 2 out of 5, were included in this systematic review. Mesalazine results in significantly less disease recurrence and fewer symptoms after an acute episode. The use of probiotics decreases symptoms but does not reduce recurrence. No difference in effect is seen when Balsalazide is added to probiotics compared to probiotics only. No relevant studies on dietary therapy/advices or antibiotics for prevention of recurrent diverticulitis were found.

Conclusion

The evidence that supports medical therapy to prevent recurrent diverticulitis is of poor quality. Treatment with 5-aminosalicylic acid seems promising. Based on current data, no recommendation of any non-operative relapse prevention therapy for diverticular disease can be made.

Stollman NH, Raskin JB (1999) Diagnosis and management of diverticular disease of the colon in adults: ad hoc practice parameters committee of the American college of gastroenterology. Am J Gastroenterol 94:3110–3121PubMedCrossRef

Colcock BP (1958) Surgical management of complicated diverticulitis. N Engl J Med 259:570–573PubMedCrossRef

Parks TG (1969) Natural history of diverticular disease of the colon: a review of 521 cases. Br Med J 4:639–642PubMedCrossRef

Rafferty J, Shellito P, Hyman NH et al (2006) Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 49:939–944PubMedCrossRef

Chautems RC, Ambrosetti P, Ludwig A et al (2002) Long term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory? Dis Colon Rectum 45:962–966PubMedCrossRef

Hjern F, Josephson T, Altmans D et al (2008) Outcome of younger patients with acute diverticulitis. Br J Surg 95:758–764PubMedCrossRef

Chapman J, Dozois E, Wolff B et al (2006) Diverticulitis: a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 243:876–883PubMedCrossRef

Hart AR, Kennedy JH, Stebbings WS et al (2000) How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 12:661–666PubMedCrossRef

Richards RJ, Hammitt JK (2002) Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis. Dig Dis Sci 47:1903–1908PubMedCrossRef

10.

Salem L, Veenstra DL, Sullivan SD et al (2004) The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg 199:904–912PubMedCrossRef

11.

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef

12.

Tursi A, Brandimarte G, Daffina (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–5PubMedCrossRef

13.

Dughera L, Serra AM, Battaglia E et al (2004) Acute recurrent diverticulitis is prevented by administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 50:49–53

14.

Tursi A, Brandimarte G, Giorgetti GM et al (2007) Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 22:1103–1108PubMedCrossRef

15.

Burkitt DP, Walker AR, Painter NS (1972) Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 2:1408–1412PubMedCrossRef

16.

Hyland JM, Taylor I (1980) Does a high fibre diet prevent the complications of diverticular disease? Br J Surg 67:77–79PubMedCrossRef

17.

Kohler L, Sauerland S, Neugebauer E (1999) Diagnosis and treatment of diverticular disease: results of a consensus development conference. Surg Endosc 13:430–436PubMedCrossRef

18.

Ludeman L, Warren BF, Shepherd N (2002) The pathology of diverticular disease. Best Pract Res Clin Gastroenterol 16:543–562PubMedCrossRef

19.

Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802CrossRef

20.

Rogler G, Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22:382–389PubMedCrossRef

21.

Tursi A, Brandimarte G, Giorgetti GM et al (2006) Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 52:671–674CrossRef

22.

Di Mario F, Aragona G, Leandro G et al (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50:581–586PubMedCrossRef

23.

Tursi A, Brandimarte G, Giorgetti GM et al (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40:312–316PubMedCrossRef

24.

Comparato G, Fanigliulo L, Cavallaro LG et al (2007) Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 52:2934–2941PubMedCrossRef

25.

Tursi A (2004) Diverticular disease of the colon. Lancet 363:1397–1398PubMedCrossRef

26.

Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38:S2–S7PubMedCrossRef

27.

Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef

28.

Lamiki P, Tsuchiya J, Pathak S et al (2010) Probiotics in Diverticular Disease of the Colon: an Open Label Study. J Gastrointest Liver Dis 19(1):31–6

29.

Papi C, Ciaco A, Koch M et al (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital J Gastroenterol 24:452–456PubMed

30.

Latella G, Pimpo MT, Sottili S et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRef

31.

Papi C, Ciaco A, Koch M et al (1995) Diverticular Disease Study Group: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre doubleblind placebo-controlled trial. Aliment Pharmacol Ther 9:33PubMedCrossRef

32.

Porta E, Germano A, Ferrieri A et al (1994) The natural history of diverticular disease of the colon: a rol for antibiotics in preventinbg complications? Eur Rev Med Pharmacol Sci 16:33–39

33.

Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H (2011) How to diagnose acute left-sided colonic diverticulitis: proposal for a clinical scoring system. Ann Surg 253(5):940–6PubMedCrossRef

34.

Lameris W, van Randen A, van Gulik TM, Busch OR, Winkelhagen J, Bossuyt PM et al (2010) A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 53:896–904PubMedCrossRef

35.

Phase III, randomised double blind dose–response stratified placebo controlled study of evaluating the safety and efficacy of SPD476 versus placebo over 104 weeks in the prevention of recurrence of diverticulitis (PREVENT 2). Clinical.Trials. gov.Identifier (http://www.clinicaltrials.gov): NCT00545103. Principal Investigator: Raskin JB, University of Miami Miller School of Medicine, USA

Title: Systematic review of medical therapy to prevent recurrent diverticulitis
Authors: Çagdas Ünlü
Lidewine Daniels
Bart C. Vrouenraets
Marja A. Boermeester
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 9/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-012-1486-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systematic review of medical therapy to prevent recurrent diverticulitis

Abstract

Aim and background

Objectives

Method and search strategy

Study selection

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim and background

Objectives

Method and search strategy

Study selection

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2012

An unusual case of a retrorectal neuroendocrine tumor with high- and low-grade differentiation

The association between arteriosclerosis related diseases and diverticular bleeding

Hereditary nonpolyposis colorectal cancer (Lynch syndrome I) in a 15-year-old male

A prospective non-randomized two-centre study of patients with passive faecal incontinence after birth trauma and patients with soiling after anal surgery, treated by elastomer implants versus rectal irrigation

Laparoscopic resection for sigmoid and rectosigmoid colon cancer performed by trainees: impact on short-term outcomes and selection of suitable patients

Endoscopic transluminal abscess drainage for Hinchey II colonic diverticulitis